Black Rock Inc. Protalix Bio Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,310,517 shares of PLX stock, worth $3.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,310,517

Previous 3,457,734 4.26%

Holding current value

$3.48 Million

Previous $6.15 Million 32.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.22 - $1.82 $179,604 - $267,934	-147,217 Reduced 4.26%	3,310,517 $4.17 Million
Q4 2023 Feb 13, 2024	BUY	$1.34 - $1.85 $378,244 - $522,203	282,272 Added 8.89%	3,457,734 $6.15 Million
Q3 2023 Nov 13, 2023	BUY	$1.49 - $2.02 $796,391 - $1.08 Million	534,491 Added 20.24%	3,175,462 $5.27 Million
Q2 2023 Aug 11, 2023	BUY	$2.0 - $3.36 $5.05 Million - $8.48 Million	2,524,828 Added 2173.9%	2,640,971 $5.28 Million
Q1 2023 May 12, 2023	BUY	$1.37 - $2.16 $19,522 - $30,780	14,250 Added 13.99%	116,143 $243,000

Q4 2022 Feb 13, 2023	BUY	$1.02 - $1.37 $3,192 - $4,288	3,130 Added 3.17%	101,893 $139,000
Q3 2022 Nov 14, 2022	SELL	$1.03 - $1.24 $2,873 - $3,459	-2,790 Reduced 2.75%	98,763 $103,000
Q2 2022 Aug 12, 2022	SELL	$1.02 - $1.56 $7,658 - $11,712	-7,508 Reduced 6.88%	101,553 $111,000
Q1 2022 May 12, 2022	SELL	$0.81 - $1.17 $4,322 - $6,244	-5,337 Reduced 4.67%	109,061 $116,000
Q4 2021 Feb 10, 2022	SELL	$0.81 - $1.33 $4,177 - $6,858	-5,157 Reduced 4.31%	114,398 $95,000
Q3 2021 Nov 09, 2021	SELL	$1.31 - $1.87 $3,856 - $5,505	-2,944 Reduced 2.4%	119,555 $159,000
Q2 2021 Aug 11, 2021	BUY	$1.86 - $6.22 $227,848 - $761,943	122,499 New	122,499 $234,000

Others Institutions Holding PLX

# of Institutions

Shares Held

9.27M

Call Options Held

40.6K

Put Options Held

10.1K

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $52.2M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account